


Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer


Seung Yeob Hyun, Huong Thuy Le, Cong-Truong Nguyen, Young-Sik Yong, Hye-Jin Boo, Ho Jin Lee, Ji-Sun Lee, Hye-Young Min, Jihyae Ann, Jie Chen, Hyun-Ju Park, Jeewoo Lee, Ho-Young Lee

Figure 3c


H1299 anti-Cleaved PARP : 89 kDa



H1299 anti-Actin: 45 kDa



H460 anti-cleaved PARP (89 kDa)



H460 anti-actin (45 kDa)






Figure 5a


H1299 anti-HIF1 α (120 kDa)



H1299 anti-Tubulin (55 kDa)



H460 anti-HIF-1 α : 120 kDa



H460 Anti-Actin: 45 kDa






Figure 5b


H1299 anti- EGFR (175 kDa)




H1299 anti-IGF1R (95 kDa)




H1299 anti-Akt (60 kDa)




H1299 anti-Tubulin (55 kDa)




H1299 anti-MEK1/2 (45 kDa)




H460 anti- EGFR (175 kDa)




H460 anti-IGF1R (95 kDa)



H460 anti-Akt (60 kDa)



H460 anti-Tubulin (55 kDa)



H460 anti-MEK1/2 (45 kDa)




Figure 5g







Figure 6a


H1299 Anti-HIF-1 α : 120 kDa



H1299 Anti-Hsp90 : 90 kDa



H460 Anti-HIF-1 α : 120 kDa



H460 Anti-Hsp90 : 90 kDa




Figure 6a





Figure 6b





Figure 6c

FL-Hsp90 (90 kDa)




100 kDa
75 kDa
63 kDa
48 kDa
35 kDa
25 kDa
20 kDa
17 kDa

N-Hsp90 (45 kDa)




100 kDa
75 kDa
63 kDa
48 kDa
35 kDa
25 kDa
20 kDa
17 kDa

M-Hsp90 (29 kDa)



100 kDa
75 kDa
63 kDa
48 kDa
35 kDa
25 kDa


C-Hsp90 (27 kDa)



100 kDa
75 kDa
63 kDa
48 kDa
35 kDa
25 kDa
20 kDa
17 kDa

Figure 6d

N-Hsp90 (45 kDa)



C-Hsp90 (27 kDa)

